- Azelis reported first-quarter revenue at €1.10 billion, missing the estimated €1.12 billion.
- The company’s gross margin was 24%, slightly below the expected 24.9%.
- Adjusted EBITA totaled €119.7 million, not meeting the forecasted €132.7 million.
- Free cash flow was recorded at €120.3 million.
- The company achieved a 2.5% organic revenue growth in the first quarter.
- Global tariff discussions have introduced uncertainty, affecting sentiment and order visibility.
- Azelis remains confident in their strategic approach to navigate trade uncertainties while capitalizing on industry opportunities.
- Analyst ratings include 14 buys, 2 holds, and 0 sells, indicating positive market sentiment.
A look at Azelis Group NV Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 2.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts are pointing towards a moderate to positive long-term outlook for Azelis Group NV, a company that wholesales and distributes chemicals globally. Based on the Smartkarma Smart Scores, Azelis Group NV has achieved a rating of 3 for both its value and growth potential, indicating a solid standing in terms of its market value and future expansion prospects.
Additionally, the company has been awarded a score of 3 for both resilience and momentum, suggesting that Azelis Group NV demonstrates stability in the face of challenges and a steady pace of development. However, its dividend score is rated at 2, indicating a slightly lower performance in terms of dividend payouts compared to other factors. Overall, Azelis Group NV‘s balanced scores across different categories position it well for potential growth and stability in the long run.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
